In fact, in the coBRIM trial, a randomized, double-blind, placebo-controlled phase III study, the combination of vemurafenib and cobimetinib, a MEK inhibitor, was associated with a significant improvement in progression-free survival in previously untreated patients with BRAFV600E-mutated advanced melanoma when compared with vemurafenib monotherapy (Larkin et al., 2014). This evidence concerns the gene MAP2K7 and melanoma.